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Abstract
 
IL-12 is essential for T helper 1 (Th1) development and in-
hibits the induction of Th2 responses. Atopic diseases,
which are characterized by Th2 responses, are associated
with the overproduction of histamine. Here we present
evidence that histamine, at physiological concentrations,
strongly inhibits human IL-12 p40 and p70 mRNA and pro-
tein production by human monocytes. The use of specific
histamine receptor antagonists reveals that this inhibition is
mediated via the H
 
2
 
 receptor and induction of intracellular
cAMP. The inhibition of IL-12 production is independent of
IL-10 and IFN-
 
g
 
. The observation that histamine strongly
reduces the production of the Th1-inducing cytokine IL-12
implies a positive feedback mechanism for the development
of Th2 responses in atopic patients. (
 
J. Clin. Invest.
 
 1998.
102:1866—1873.) Key words: cytokines 
 
¥
 
 allergy and immu-
nology 
 
¥
 
 Th1 cells 
 
¥
 
 monocytes 
 
¥
 
 interferon gamma
 
Introduction
 
Two distinct subsets of CD4
 
1
 
 T helper (Th)
 
1
 
 cells with differ-
ent cytokine profiles and functions have been shown to de-
velop from naive precursors. Th1 cells produce IL-2, IFN-
 
g
 
,
and TNF-
 
b
 
, activate macrophages, and cause delayed type hy-
persensitivity reactions, whereas Th2 cells produce IL-4, IL-5,
IL-10, and IL-13, cause eosinophilia, and induce an immuno-
globulin class switch to IgG1 (mouse) or IgG4 (human) and
IgE (1—3). Aberrant regulation of Th1 or Th2 responses leads
to immunopathology; in patients with HIV infection and aller-
gic patients, T helper cells are believed to have shifted toward
a Th2 response (4—6), while various organ-specific autoim-
mune diseases are characterized by Th1-like responses (7).
Recently, it has become clear that the APC-derived factor
IL-12 is instrumental for development of a Th1 response (8).
Only the IL-12 p70 heterodimer, consisting of a p40 and p35
chain, encoded by two separate genes, is biologically active (9).
No biological function is known for the single p40 chain, which
is secreted in excess over the p70 protein. IL-12 induces prolif-
eration and IFN-
 
g
 
 production and enhances cytolytic activity
in T cells and NK cells (10, 11). In contrast, in the absence of
IL-12, a Th2 response is able to develop (8, 12). Therefore,
modulation of IL-12 production during an immune response is
crucial for the outcome of disease. The Th1 product IFN-
 
g
 
provides a positive feedback on Th1 development by its capac-
ity to strongly upregulate the production of IL-12 by mono-
cytes (13—15). Endogenous inhibitors of human IL-12 produc-
tion are IL-10, IL-4, IL-13, and TGF-
 
b
 
 (16, 17) and members
of the complement system. Ligation of iC3b with complement
receptor 3 and cross-linking of CD46 by C3b or measles virus
also inhibits the production of IL-12 (18, 19). We previously
stated that cAMP-inducing agents such as prostaglandin E
 
2
 
(PGE
 
2
 
) are strong inhibitors of IL-12 p40 production, while
upregulating IL-10 production in LPS-stimulated human mono-
cytes (20). Thereafter, it was reported that 
 
b
 
2
 
 agonists also in-
hibited human IL-12 production and Th1 development by in-
creasing intracellular cAMP (21).
Histamine is an endogenous mediator of many (patho)-
physiological processes, such as the regulation of gastric acid
secretion and cardiac output, while functioning as a neu-
rotransmitter in the brain (for reviews see references 22 and
23). During allergic reactions, histamine is released in large
quantities from intracellular stores from mast cells and baso-
phils after cross-linking of cell surface IgE by allergens. Based
on the activity of various selective agonists and antagonists,
three types of histamine receptors have been described, desig-
nated H
 
1
 
, H
 
2
 
, and H
 
3
 
. Signaling through the H
 
1
 
 receptor in-
volves the activation of PLC, leading to the generation of
1,4,5-inositol phosphate and DAG, whereas H
 
2
 
 receptor stim-
ulation results in cAMP generation (22, 23). H
 
1
 
 and H
 
2
 
 recep-
tors are expressed on many cell types, including lymphoid cells
(24—26). The immune modulating effects of histamine include
inhibition of IL-2 and IFN-
 
g
 
 production by T cells and inhibi-
tion of TNF-
 
a
 
 and IL-1 production by monocytes (27—29).
Less is known about the H
 
3
 
 receptor; its expression is observed
in the brain (in addition to H
 
1
 
 and H
 
2
 
 receptors), but on lym-
phoid cells its expression is not well studied. Indirect evidence
indicates the presence of H
 
3
 
 receptors on eosinophils (30). The
signaling pathway of this receptor is largely unknown. In the
present study, we report that H
 
2
 
 receptor stimulation inhibits
IL-12 production by monocytes. This observation leads to new
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b
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prostaglandin E
 
2
 
; RT,
reverse transcriptase; SAC, 
 
Staphylococcus aureus
 
 Cowan I strain;
Th1, T helper 1 cell.
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concepts on the role of histamine during allergic reactions and
T helper development.
 
Methods
 
Antibodies and reagents
 
The anti—IL-12 mAbs, reacting with both IL-12 p40 and p70, C11.79
and C8.6 (31), were kindly provided by Dr. G. Trinchieri (The Wistar
Institute, Philadelphia, PA). mAb 20C2, specific for IL-12 p70, was a
kind gift from Dr. M.K. Gately (Hoffmann-LaRoche, Nutley, NJ).
Anti—IL-10 mAb B-T10 and B-N10 were a kind gift from Dr. J.
Wijdenes (Diaclone, Besancon, France). PGE
 
2
 
 was obtained from
Sigma Chemical Co. (St. Louis, MO). rhIL-10 was a kind gift from
Dr. R. de Waal Malefijt (DNAX, Palo Alto, CA). 
 
Staphylococcus au-
reus
 
 Cowan I strain (SAC, Pansorbin) was obtained from Calbiochem
(La Jolla, CA), histamine dihydrochloride and triprolidine dihydro-
chloride from Sigma Chemical Co., and ranitidine dihydrochloride
from Glaxo (Middlesex, UK). Clobenpropit dihydrobromide and
amthamine dihydrobromide were synthesized at the Free University
(Department of Pharmacochemistry, Amsterdam, The Netherlands).
 
Whole blood cultures
 
Whole blood was obtained by venepuncture from normal healthy do-
nors in sodium-heparin—containing sterile blood collecting tubes
(VT-100SH tubes, Venoject; Terumo Europe N.V., Leuven, Bel-
gium). To prevent spontaneous production of cytokines by endotoxin
or endotoxin-like substances present in culture media, IMDM was ul-
trafiltrated by means of a hollow-fiber dialyzer (32) (Hemoflow F5;
Fresenius A.G., Bad Homburg, Germany). Whole blood was diluted
1:10 in ultrafiltrated IMDM, supplemented with 0.1% FCS, penicillin
(100 IU/ml), streptomycin (100 
 
m
 
g/ml), and 15 IU/ml sodium heparin
(Leo Pharmaceutical Products B.V., Weesp, The Netherlands). Di-
luted whole blood was cultured in triplicate in 200-
 
m
 
l flat-bottomed
culture plates (Nunc, Roskilde, Denmark) and stimulated with SAC
(0.01% wt/vol). Histamine, agonist, antagonists, or PGE
 
2
 
 were added
simultaneously with SAC. Supernatants were harvested after 18—24 h
of culture, and cytokine levels were determined.
 
Assays for cytokines
 
IL-12 p70 ELISA.
 
Flat-bottomed microtiter plates (Maxisorb; Nunc)
were coated overnight with mAb 20C2 (0.5 
 
m
 
g/ml in 0.1 M carbonate
buffer, pH 9.6, 100 
 
m
 
l/well). All subsequent incubations were in 100-
 
m
 
l volumes at room temperature. The plates were washed twice with
PBS, 0.02% (vol/vol) Tween 20, and incubated for 30 min with PBS
containing 2% (vol/vol) cowÕs milk as a blocking step. After washing,
biotinylated purified mAb C8.6 was added (final concentration 0.25
 
m
 
g/ml) together with IL-12 containing samples diluted in high-perfor-
mance ELISA buffer (CLB, Amsterdam, The Netherlands) for 1.5 h.
Thereafter, the plates were washed five times and incubated with
poly-streptavidin-horseradish peroxidase (CLB), 1:10,000 diluted (ac-
cording to the manufacturerÕs instructions) in PBS containing 2%
(vol/vol) cowÕs milk for 0.5 h, washed, and developed with a solution
of 100 
 
m
 
g/ml of 3,5,3
 
9
 
,5
 
9
 
-tetramethylbenzidine (Merck, Darmstadt,
Germany) with 0.003% (vol/vol) H
 
2
 
O
 
2
 
 in 0.11 M sodium acetate, pH
5.5 (100 
 
m
 
l/well). The reaction was stopped by adding an equal vol-
ume of 2 M H
 
2
 
SO
 
4
 
 to the wells. Plates were read at 450 nm in a Titer-
tek Multiskan reader. Background absorbance at 540 nm was sub-
tracted. rhIL-12 p70, provided by Dr. S.F. Wolf (Genetics Institute
Inc., Cambridge, MA), was used as a standard and the detection
limit was 0.5 pg/ml (twice the background). This assay does not de-
tect free p40 (provided by Dr. S.F. Wolf, Genetics Institute, Inc.) up
to 20 ng/ml.
 
IL-12 ELISA.
 
IL-12 ELISA detects both p40 and p70 (20) and
was performed identical to the p70-specific ELISA with the excep-
tion that the coating antibody was replaced by mAb C11.79, which
was used at 2 
 
m
 
g/ml. IL-12 containing culture supernatant, standard-
ized to rhIL-12 p70 (provided by Dr. S.F. Wolf, Genetics Institute,
Inc.), was used as a standard. The detection limit was 4 pg/ml (twice
the background).
 
IL-10 ELISA.
 
IL-10 ELISA assay was performed identical to the
IL-12 ELISA, except that the blocking step was omitted (20). For
coating, mAb B-N10 was used at 0.5 
 
m
 
g/ml in PBS, and for detection,
biotinylated mAb B-T10 was used at 0.125 
 
m
 
g/ml. rhIL-10 was used as
a standard.
 
IL-6 ELISA.
 
Procedures were identical to the IL-12 ELISA, ex-
cept that the blocking step was eliminated and for coating anti—IL-6,
mAb CLB.IL6/16 was used at 1 
 
m
 
g/ml in PBS. Affinity-purified bioti-
nylated polyclonal sheep anti—IL-6 was used for detection at 0.25 
 
m
 
g/
ml (33). rhIL-6 (34) was used as a standard. The detection limit was 1
pg/ml.
 
Competitive reverse transcriptase (RT)-PCR
 
Whole blood (see above) was stimulated with SAC in the absence or
presence of 10 ng/ml IFN-
 
g
 
 (Boehringer Mannheim, Almere, The
Netherlands). Total cellular RNA was extracted using TRIzol Re-
agent (GIBCO BRL/Life Technologies, Gaithersburg, MD) accord-
ing to manufacturerÕs instructions. After determination of A
 
260
 
 and
A
 
280
 
, 1 
 
m
 
g of RNA was transcribed to cDNA for 1 h at 37
 
8
 
C in 20-
 
m
 
l
reaction volumes containing 1
 
3
 
 RT buffer, 200 U of Superscript RT
(GIBCO BRL), oligo(dT) primer (GIBCO BRL), 0.01 M dithiothrei-
tol, and 0.5 mM dNTPÕs (Promega, Madison, WI). The reaction was
terminated by a 10-min incubation at 95
 
8
 
C.
Cellular cDNA was amplified together with twofold diluted titra-
tions of an internal competitive standard of plasmid IL-12 and 
 
b
 
2-
microglobulin (
 
b
 
2-M) cDNA, pQB3, a kind gift from D. Shire (Sanofi
ELF Bio Recherches, Labge, France) (35). The internal standard
binds to the same primer set but yields a PCR product of a different
length. PCR reactions were carried out in 1
 
3
 
 PCR buffer supple-
mented with 1.5 mM MgCl
 
2
 
, 0.2 mM dNTPÕs, 750 nM of each primer;
for IL-12 p40: sense primer; ATTGAGGTCATGGTGGATGC, an-
tisense primer; AATGCTGGCATTTTTGCGGC, and 
 
b
 
2-M: sense
primer: CCAGCAGAGAATGGAAAGTC, antisense primer:
GATGCTGCTTACATGTCTCG (GIBCO BRL), and 1.25 U of
Taq polymerase (GIBCO BRL) in a final volume of 25 
 
m
 
l. cDNA was
denatured for 5 min at 95
 
8
 
C, followed by 35 cycles of amplification:
95
 
8
 
C for 45 s, 59
 
8
 
C for 45 s, and 72
 
8
 
C for 2 min. After the last cycle,
the samples were incubated at 72
 
8
 
C for 10 min. The amplified prod-
ucts were separated by agarose gel electrophoresis in the presence of
ethidium bromide and visualized by ultraviolet light to identify bands
of equal intensity. 
 
Results
 
Human IL-12 production is strongly reduced by histamine.
 
Various bacterial stimuli induce cytokine production in whole
blood cultures with different efficacies; both LPS, heat-killed
 
Escherichia coli
 
 and formalin-fixed SAC lead to IL-12 p40 pro-
duction, but only SAC leads to significant IL-12 p70 produc-
tion (14, 36, 37). Histamine, a mediator tightly connected to
the effector phase of atopy, caused a strong reduction of IL-12
p40 and p70 production induced by SAC (Fig. 1). IL-12 p40
production induced by 
 
E. coli
 
 was inhibited to the same extend
by histamine (not shown). In 15 donors, concentrations as low
as 10
 
2
 
8
 
 M histamine led to a mean inhibition of IL-12 p70 pro-
duction of more than 50% (Fig. 1). In the same cultures, pro-
duction of IL-10 was approximately twofold enhanced in the
presence of 10
 
2
 
7
 
 M histamine, whereas IL-6 production was
not affected. To rule out the possibility that the effect of hista-
mine on IL-12 is indirect via IL-10, we repeated the experi-
ment in the presence of excess neutralizing antibodies to IL-
10. Fig. 2 shows that IL-10 is not involved in the inhibition of
IL-12 production by histamine.
 1868
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Histamine inhibits IL-12 production at the level of mRNA
production.
 
We studied the effect of histamine on IL-12 p40
mRNA production using a competitive RT-PCR. First, we ex-
amined the kinetics of IL-12 mRNA production. A 6-h stimu-
lation (in the absence or presence of IFN-
 
g
 
) turned out to be
optimal for IL-12 mRNA production (data not shown). We
subsequently analyzed the effect of histamine on the produc-
tion of IL-12 p40 mRNA after a 6-h stimulation with SAC with
or without IFN-
 
g
 
 (Fig. 3). The amount of IL-12 p40 cDNA is
expressed relative to the amount of 
 
b
 
2-microglobulin cDNA
as a measure for the amount of mRNA isolated (Fig. 3 
 
B
 
). The
production of IL-12 p40 mRNA was reduced to 
 
,
 
 10% by his-
tamine, irrespective of the presence of IFN-
 
g
 
. The reduction of
IL-12 p40 mRNA was accompanied by an equal reduction in
IL-12 p40 protein production (measured after 24 h of stimula-
tion; Fig. 3 
 
B
 
). The fact that this inhibition also occurred in the
presence of IFN-
 
g
 
 indicates that the inhibition of histamine is
not indirect through an inhibitive effect on IFN-
 
g
 
 production.
 
Histamine directly affects monocyte IL-12 production.
 
We
have shown before that in whole blood, IL-12 production is de-
rived from monocytes (20, 37). It could be argued that the ob-
served inhibition of IL-12 production by histamine in whole
blood cultures is indirect through another cell type. Therefore,
we examined the effect of histamine on purified monocytes.
Because the production of IL-12 is very low in isolated mono-
cytes (36), IFN-
 
g
 
 was added as a costimulator of SAC or LPS.
Under these conditions, histamine inhibited the production of
IL-12 to a similar extent as was observed in whole blood cul-
tures (data not shown). Therefore, we conclude that histamine
targets the monocyte directly.
 
Histamine-induced inhibition of IL-12 production can be re-
versed by an H
 
2
 
 antagonist.
 
Three different receptors, H
 
1
 
, H
 
2
 
,
and H
 
3
 
, mediate the biological effects of histamine. We ana-
lyzed which receptor was involved in the inhibition of IL-12
production using specific receptor antagonists. Triprolidine,
Figure 1. Effects of histamine on 
IL-12 p40 and p70, IL-6, and IL-10 
production. Whole blood (1:10 di-
luted) was stimulated with SAC in 
the absence or presence of indicated 
concentrations of histamine. Results 
are the mean cytokine production6 
SE of 15 donors (p40, p70, and IL-6), 
for IL-10 the mean of six donors6 
SE is shown.
Figure 2. Inhibition of IL-12 p70 (A) and p40 (B) is independent of 
IL-10. Whole blood was stimulated with SAC in the absence (s) or 
presence (d) of histamine and anti—IL-10. Anti—IL-10 mAb BT-10 
was used at 5 mg/ml, IL-10 at 600 pg/ml. The results are the mean pro-
duction (6SE) of four donors. The mean IL-12 p70 and p40 produc-
tion without addition of histamine or anti—IL-10 were 45 pg/ml and 
1045 pg/ml, respectively.
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ranitidine, and clobenpropit selectively compete with the ac-
tivity of histamine on H
 
1
 
, H
 
2
 
, and H
 
3
 
 receptors, respectively
(22). Their antagonistic capacities are expressed as pA
 
2
 
 values,
i.e., the negative logarithm of the concentration required to get
50% reduction of the efficacy of histamine. For triprolidine, a
pA
 
2
 
 value of 9.7 has been found, for ranitidine 7.2, and for
clobenpropit 9.9 (22). For all three antagonists, we tested the
effect of 100-fold the pA
 
2
 
 value. Only ranitidine, the H
 
2
 
 antag-
onist, reversed the inhibition by histamine of IL-12 p40 as well
as p70 production. Neither the H1 nor the H3 antagonist had
any effect (Fig. 4, A and B). More detailed analysis of the ra-
nitidine effect (Fig. 4, C and D) allowed calculation of the pA2
value for ranitidine in this system. The obtained pA2 values,
7.2 and 7.3 for p70 and p40, respectively, correspond to the re-
ported histamine-antagonizing potency of ranitidine. In this
respect, the H2 receptor on monocytes functions identically to
H2 receptors on nonlymphoid cells and is responsible for the
inhibition of IL-12 production by histamine.
Specific stimulation of histamine H2 receptors by an H2 ago-
nist inhibits the production of IL-12. To confirm that the inhi-
bition of IL-12 production was due to specific interaction of
histamine with H2 receptors, we also examined the effect of
amthamine, a specific H2 agonist. Amthamine has been de-
scribed to be 1.6 times more potent than histamine on H2 re-
ceptors but to have hardly any activity on H1 and H3 receptors
(22). This was confirmed in our experiments because the IC50
values for amthamine and histamine were 1.8 3 1028 and 5 3
1028 for p40 production and 1.4 3 1028 and 3.6 3 1028 for p70
production, respectively, in the same donors (Fig. 5). As ex-
pected, the inhibition of IL-12 production by amthamine (and
histamine) could again be reversed by an excess of the H2 an-
tagonist ranitidine.
Histamine and PGE2 have additive effects on the inhibition
of IL-12 production. The inhibitive activities of histamine and
PGE2 on IL-12 production were compared and examined for
possible synergistic effects (Fig. 6). PGE2 appeared to be more
potent than histamine at 1029 and 1028 M in inhibiting IL-12
production, but at 1027 M there was no difference in activity.
The combination of histamine and PGE2 resulted in a cumula-
tive effect on the inhibition of IL-12 production, without any
synergism.
Discussion
The present data indicate that histamine is an important inhib-
itor of the production of IL-12 by monocytes. Although SAC is
an activator of both B cells and monocytes, B cells hardly con-
tribute to the production of IL-12 (38). In whole blood cul-
tures, monocytes are considered the main IL-12— and IL-6—
producing cells, because CD14-depleted MNC or granulocytes
did not produce IL-12 or IL-6 after stimulation with SAC. In
agreement with a direct inhibitive effect of histamine on the
production of TNF-a and IL-1 in isolated monocytes (28, 29),
we also observed an inhibition of IL-12 production by hista-
mine in isolated monocytes, which could be reversed by an H2
antagonist (data not shown).
PGE2 (after interaction with the PGE2 receptor) and hista-
mine (through interaction with the H2 receptor) activate ade-
nylate cyclase, which leads to the generation of increased lev-
els of cAMP in various cell types (22, 23). In previous reports,
we showed that the effects of PGE2 on IL-12 p40, TNF-a, and
IL-10 production by LPS-stimulated human monocytes in
whole blood cultures could all be mimicked by cAMP (20, 36).
In agreement with others (39), we observed increased levels of
Figure 3. Inhibition of IL-12 p40 mRNA and pro-
tein by histamine. (A) Whole blood was stimu-
lated with: lane 1, SAC; lane 2, SAC and hista-
mine 1026 M; lane 3, SAC and IFN-g; lane 4, SAC, 
IFN-g and histamine 1026 M. RT products of cel-
lular IL-12 p40 and b2-M mRNA were quantified 
by coamplification with graded amounts of stan-
dard cDNA. The upper band represents plasmid 
cDNA, and the lower band represents cellular 
cDNA. For b2-M, 0.1 ml of the RT product was 
used in each PCR reaction. For IL-12, the quanti-
ties of RT products were: lane 1, 0.1 ml; lane 2, 0.2 
ml; lane 3, 0.05 ml; and lane 4, 0.1 ml for the same 
standard cDNA titrations. (B) The amount of IL-
12 p40 mRNA is expressed relative to the amount 
of b2-M. The amount of IL-12 p40 protein is mea-
sured after 24 h of culture. Representative results 
of one out of three experiments are shown.
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cAMP in purified monocytes after incubation with histamine,
which could be prevented by an H2 antagonist (data not
shown). Because both the inhibition of IL-12 production and
enhancement of cAMP levels by histamine were mediated
through the H2 receptor and the combined effects of histamine
and PGE2 on IL-12 production were additive, histamine and
PGE2 most likely inhibit IL-12 production by a similar cAMP-
dependent mechanism. The exact pathway of cAMP-induced
inhibition of IL-12 production is presently unknown. In T cells,
a cAMP-inducible transcriptional repressor protein (ICER, in-
ducible cAMP early repressor) has been described that inhib-
its IL-2 promoter activity (40). This mechanism probably in-
volves binding of ICER to cAMP responsive elements (CRE),
thereby inhibiting transactivating CRE-binding proteins. A
similar mechanism may be responsible for the cAMP-induced
inhibition of IL-12 production, since the human IL-12 p40 pro-
moter contains a CRE-like motif (15). Another explanation
may be reduced activation of NF-kB through cAMP-induced
retardation of degradation of the inhibitor of NF-kB, IkBa
(41). Murine p40 transcription has been shown to be positively
regulated by NF-kB (42). Because the human IL-12 p40 pro-
moter contains a NF-kB site (15), this may also be true for hu-
man p40 regulation.
Interestingly, both PGE2 and histamine are associated with
Th2-mediated (allergic) diseases. Histamine is released during
allergic reactions after interaction of allergens with cell-bound
IgE on basophils and mast cells. PGE2 is overproduced by
Figure 4. Reversal of histamine-induced inhibition of IL-12 produc-
tion by a H2 antagonist. Whole blood (1:10 diluted) was stimulated 
with SAC and graded concentrations of histamine, in the absence or 
presence of different histamine antagonists as indicated. (A and B) 
Ranitidine (H2 antagonist, pA2 7.2), triprolidine (H1 antagonist, pA2 5 
9.7), and clobenpropit (H3 antagonist, pA2 5 9.9) were all tested at 
100-fold the pA2 value. (C and D) Ranitidine was used at 10-, 100-, 
and 1,000-fold its pA2 value. Results are the mean production of four 
donors6SE. In the absence of histamine or antagonists, mean p70 
production was 83 pg/ml, and mean p40 production was 1,696 pg/ml.
Figure 5. Inhibition of IL-12 production by the H2 agonist amtha-
mine in comparison with histamine. Whole blood (1:10 diluted) was 
stimulated with SAC and the indicated concentrations of amthamine 
and histamine. The H2 antagonist ranitidine (R) was used at 1024 M. 
Results are the mean production of four donors6SE. In the absence 
of histamine or agonists/antagonists, mean IL-12 p70 and p40 produc-
tion were 108 pg/ml and 2,023 pg/ml, respectively.
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PBMCs from atopic dermatitis and hyper-IgE patients (43,
44). In addition, PBMCs from atopic dermatitis patients show
enhanced basal activation of PKA and increased levels of
cAMP (45). In allergic asthma patients with enhanced IgE lev-
els, we found a reduced capacity to produce IL-12 p70 in re-
sponse to SAC (37). The in vivo exposure of monocytes to his-
tamine and PGE2 could have contributed to this. Similar
observations were reported on HIV-infected patients. A re-
duced production of IL-12 and an enhanced production of
PGE2 (46—48) by PBMCs from these patients was observed.
However, even after stimulation conditions with normal pro-
duction of PGE2 or after blockage of the production of PGE2,
the production of IL-12 is reduced in these patients (49, 50).
Because HIV infection is accompanied by increased serum
levels of PGE2 (51) and enhanced levels of intracellular cAMP
and basal PKA activation (52), the in vivo production of PGE2
by other cell types or other cAMP-inducing agents such as his-
tamine or b-adrenergic agonists may be responsible for the re-
duced production of IL-12. Although the role of histamine in
HIV infection seems far fetched, treatment of AIDS related
complex patients with an H2 antagonist has been claimed to
yield beneficial effects, including improved T cell proliferation
and delayed-type of hypersensitivity (DTH) reactions (53).
Also in mice the suppression of DTH responses caused by his-
tamine can be reversed by H2 antagonists (54, 55). The in vivo
role of histamine has also been investigated in allergic rhinitis
patients. The systemic or local use of a histamine H2 antagonist
decreases the levels of IgE in serum or nasal fluid, respectively
(56, 57). Because IgE production can be considered a readout
for Th2 responses, while Th1 responses are characterized by
DTH responses, histamine is clearly positively influencing Th2
responses in vivo.
Overproduction of histamineand PGE2 can lead to Th2
responses by several mechanisms. Histamine (H2 receptor-
mediated) inhibits TNF-a production by monocytes (28), while
PGE2 and other cAMP inducers have also been reported to in-
hibit TNF-a and to enhance IL-10 production by monocytes (20,
58, 59). TNF-a may contribute to Th1 development by potentiat-
ing IL-12—induced production of IFN-g in PBMCs (16). In
addition, cAMP, histamine, and PGE2 inhibit secretion of the
Th1 cytokines IL-2 and IFN-g but not the Th2 cytokines IL-4
and IL-5 (27, 60, 61). However, the most important mechanism
of induction of Th2 development is probably the inhibition of
IL-12 production, because the concentrations of PGE2 and his-
tamine that inhibit the production of IL-12 are approximately
100- and 1000-fold lower, respectively, than those required for
inhibition of T cell cytokine production. The levels of histamine
that completely inhibit the production of IL-12 are well within
the physiological range. Histamine reaches levels as high as
1027 M in serum or nasal washing fluids (62, 63), suggesting
that concentrations of histamine in tissue may even be higher.
Initial histamine release is dependent on the presence of IgE,
induced by Th2 cytokine production. Histamine may provide a
positive feedback on continued Th2 differentiation by the inhi-
bition of IL-12. In addition, histamine enhances anti-CD58 plus
IL-4— or IL-13—induced IgE production in purified B cells (64).
Interestingly, a positive feedback loop of histamine on Th2 dif-
ferentiation appears to be more evident in allergic patients.
Basophils from allergic asthma and atopic dermatitis patients
show an increased histamine releasability compared with baso-
phils from normal controls (65—67). This may lead to reduced
IL-12 production and Th2 development, and as a result contin-
ued overproduction of IgE, a characteristic of these patients.
The observation that the cAMP/PKA pathway (possibly in-
duced by histamine or PGE2) is overactive in a number of
pathological conditions such as HIV infection and atopic dis-
eases may lead to new intervention strategies designed to up-
regulate IL-12 production. The use of inhibitors of PGE2 syn-
thesis and histamine H2 antagonists may be valuable to
redirect Th2 to Th0/Th1 responses in these conditions and may
be combined with vaccination or hyposensitization therapy.
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